TICKERNERD
Menu
HIMSHIMSHealthcare · Drug Manufacturers - Specialty & Generic

HIMS Stock Forecast: Hims & Hers Health, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$29
−0.67% on the day

The 15 Wall Street analysts covering Hims & Hers Health, Inc. hold a median 12-month price target of $31 — +5.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 6 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$6.9B
Ticker Nerd rank
17 / 100
Median analyst target
$31
Analysts covering
15
Revenue$753.2M+38.2% y/y
Operating income−$97.2M
Net income−$86.3M
Free cash flow−$68.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.7%
1M
+6.4%
YTD
−9.2%
1Y
−46.2%
From 52W high
−53.0%
From 52W low
+103.0%
$15
$63
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HIMS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Hims & Hers Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
17 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
66
Accruals
57
Revisions
40
Value
38
Growth
37
Momentum
25
Size
19
Issuance
17
Volatility
12

Quality (66): The business earns solid, repeatable profits on what it owns.

Volatility (12): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HIMS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HIMS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26HIMSHigh $42Median $31Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
3 Buy11 Hold1 Sell
Low $23Median $31High $42

The green dot is the last close — the median target sits +5.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
11 Sept 2026JP MorganAssumesNeutral$32
24 Aug 2026Truist SecuritiesMaintainsHold—
24 Aug 2026Truist SecuritiesMaintainsHold$27 → $32
21 Aug 2026BarclaysMaintainsOverweight—
21 Aug 2026BarclaysMaintainsOverweight$39 → $35
11 Aug 2026B of A SecuritiesMaintainsNeutral—
11 Aug 2026B of A SecuritiesMaintainsNeutral$30 → $32
11 Aug 2026CitigroupMaintainsNeutral—
11 Aug 2026CitigroupMaintainsNeutral$35 → $33
11 Aug 2026Deutsche BankMaintainsHold—
11 Aug 2026Deutsche BankMaintainsHold$25 → $26
11 Aug 2026Morgan StanleyMaintainsEqual-Weight$21 → $28
11 Aug 2026Morgan StanleyMaintainsEqual-Weight—
11 Aug 2026NeedhamMaintainsBuy$35 → $42
11 Aug 2026NeedhamMaintainsBuy—
11 Aug 2026TD CowenMaintainsHold$25 → $30
11 Aug 2026TD CowenMaintainsHold—
24 July 2026Truist SecuritiesMaintainsHold$23 → $27
24 July 2026Truist SecuritiesMaintainsHold—
23 July 2026CitigroupMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HIMS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

HIMS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Hims & Hers Health, Inc. returned −46.2% against +17.3% for the S&P 500, dividends included.

HIMS vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26HIMSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HIMS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Hims & Hers Health, Inc. (HIMS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
57.1×

Cheaper than 13% of US stocks

Price / sales
2.7×

Cheaper than 44% of US stocks

Price / book
21.2×

Cheaper than 4% of US stocks

EV / EBITDA
−749.5×

Cheaper than 99% of US stocks

Growth & margins
Revenue growth (YoY)
38.2%

Higher than 82% of US stocks

Earnings growth (YoY)
38.2%

Higher than 70% of US stocks

Gross margin
63.8%

Higher than 77% of US stocks

Operating margin
−12.8%

Higher than 23% of US stocks

Net margin
−5.5%

Higher than 23% of US stocks

Returns & dividend
Return on equity
−32.0%

Higher than 27% of US stocks

Return on assets
−2.2%

Higher than 36% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Hims & Hers Health, Inc. (HIMS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Hims & Hers Health, Inc. has a market value of $6.9B and an enterprise value of $7.6B.

  • Revenue in the twelve months to 30 June 2026: $2.6B. The latest quarter grew 38.2% year on year.

  • Net income over the same four quarters: −$142.0M, a −5.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.63.

  • Free cash flow in the twelve months to 30 June 2026: $61.6M.

  • Shares outstanding: 233.3M.

  • Trailing P/E: 57.1×; forward P/E: 40.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Hims & Hers Health, Inc. employs 2,442 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

HIMS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
HIMSHims & Hers Health, Inc.$6.9B
17
ALKSAlkermes Plc$6.9B
61
LNTHLantheus Holdings, Inc.$6.5B
89
AMRXAmneal Pharmaceuticals, Inc.$6.4B
83
KNSAKiniksa Pharmaceuticals International Plc$5.9B
98
INDVIndivior Pharmaceuticals, Inc.$4.2B
97
ELANElanco Animal Health, Inc.$11.2B
97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Hims & Hers Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HIMS news & analysis

Kaplan Fox Deadline Alert: Hims & Hers Health, Inc. (HIMS) Investors Have Until November 2, 2026 to Seek a Lead Plaintiff Role

Newsfile Corp · 6 Oct 2026negative

Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Hims & Hers Health, Inc. on behalf of investors who acquired its securities from August 4, 2025 through July 29, 2026. Investors have until November 2, 2026 to seek appointment as lead plaintiff.

Why it matters — The lawsuit and lead-plaintiff deadline are developments for HIMS investors to monitor.

Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PRNewsWire · 6 Oct 2026negative

Glancy Prongay Wolke & Rotter LLP announced that investors who suffered losses on Hims & Hers Health shares may seek to lead a securities fraud class action. The stated lead plaintiff deadline is November 2, 2026.

Why it matters — The announcement concerns pending securities litigation involving Hims & Hers and invites affected shareholders to participate.

HIMS Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages HIMS Investors with Losses to Contact the Firm

PRNewsWire · 5 Oct 2026negative

A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. covering the period from August 4, 2025 through July 29, 2026, alleging material misstatements and/or omissions concerning the company's deceptive and unlawful privacy practices. The law firm Kessler Topaz Meltzer & Check, LLP is encouraging affected investors to contact them, with a deadline of November 2, 2026 to seek lead plaintiff status.

Why it matters — This class action lawsuit alleging deceptive privacy practices could expose the company to legal and reputational risk and may be material to investors who purchased HIMS securities during the specified period.

Kaplan Fox Alerts Investors: Lead Plaintiff Deadline for Hims & Hers Health, Inc. (HIMS) is November 2, 2026

Newsfile Corp · 5 Oct 2026negative

Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Hims & Hers Health, Inc. on behalf of investors who purchased or acquired company securities between August 4, 2025 and July 29, 2026. The lead plaintiff deadline is November 2, 2026.

Why it matters — A HIMS watcher would care because the company is facing a securities class action lawsuit covering a defined class period, a legal and financial development investors may want to monitor.

HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law

GlobeNewsWire · 5 Oct 2026negative

A law firm, SBS, reminds Hims & Hers investors of a securities fraud class action lawsuit against the company for alleged violations of the Securities Exchange Act. Shareholders who purchased during the specified class period are encouraged to contact the firm regarding lead plaintiff appointments.

Why it matters — The securities fraud lawsuit introduces regulatory and legal risk for the company and is something shareholders should be aware of.

FAQ

Frequently asked questions about HIMS stock

What is the HIMS stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Hims & Hers Health, Inc. have a median 12-month price target of $31, with estimates ranging from $23 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HIMS stock a buy right now?

Of the 15 analysts covering Hims & Hers Health, Inc., 3 rate it a Buy, 11 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Hims & Hers Health, Inc. 17 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HIMS?

As at 6 Oct 2026, Hims & Hers Health, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (66 of 100).

Will HIMS stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +5.2% from the last close, and Ticker Nerd's factor model ranks Hims & Hers Health, Inc. 17 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HIMS stock forecast for 2030?

No analyst covering Hims & Hers Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HIMS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $42 over the next 12 months.

How has HIMS stock performed over the past year?

Hims & Hers Health, Inc. returned -46.2% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Hims & Hers Health, Inc. do?

Hims & Hers Health, Inc. Class A Common Stock is the equity of Hims & Hers Health, a consumer-focused digital health and telehealth platform.

What is the latest news on HIMS?

The most recent item we track (Newsfile Corp, 6 Oct 2026): "Kaplan Fox Deadline Alert: Hims & Hers Health, Inc. (HIMS) Investors Have Until November 2, 2026 to Seek a Lead Plaintiff Role". Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Hims & Hers Health, Inc. on behalf of investors who acquired its securities from August 4, 2025 through July 29, 2026. Investors have until November 2, 2026 to seek appointment as lead plaintiff.

Company

About Hims & Hers Health, Inc.

Hims & Hers Health, Inc. Class A Common Stock is the equity of Hims & Hers Health, a consumer-focused digital health and telehealth platform. Hims & Hers connects customers with licensed healthcare professionals through its websites and mobile app, offering online consultations, prescriptions, laboratory testing, and follow-up support. Its current product and service lineup spans sexual health, hair care, mental health, weight loss, dermatology, and general wellness, with a mix of prescription and over-the-counter offerings. The company also provides personalized health solutions and fulfillment services through its branded consumer platform. Based in San Francisco and founded in 2017, Hims & Hers operates in the healthcare market as a direct-to-consumer service provider that combines clinical access, digital technology, and pharmacy-enabled delivery.

CEO Mr. Andrew Dudum · 2,442 employees · United States · https://www.hims.com